Enveric Biosciences Inc (ENVB)

Mar 31, 2025, 8:00 AM EDT - 2 days ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 17, 2025, 1:40 PM EDT - 16 days ago

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 6, 2025, 10:00 AM EST - 27 days ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Feb 27, 2025, 9:30 AM EST - 4 weeks ago

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 25, 2025, 1:30 PM EST - 5 weeks ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 4, 2025, 8:00 AM EST - 2 months ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 3, 2025, 5:00 PM EST - 2 months ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Jan 30, 2025, 8:14 PM EST - 2 months ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Jan 30, 2025, 4:01 PM EST - 2 months ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Jan 6, 2025, 8:30 AM EST - 3 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Dec 2, 2024, 8:00 AM EST - 4 months ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Nov 25, 2024, 9:00 AM EST - 4 months ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Nov 14, 2024, 4:05 PM EST - 4 months ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Nov 12, 2024, 9:00 AM EST - 5 months ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Nov 4, 2024, 10:36 AM EST - 5 months ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Oct 15, 2024, 8:00 AM EDT - 6 months ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Sep 26, 2024, 8:30 AM EDT - 6 months ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Sep 25, 2024, 8:30 AM EDT - 6 months ago

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Sep 4, 2024, 8:00 AM EDT - 7 months ago

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 8 months ago

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Aug 12, 2024, 5:30 PM EDT - 8 months ago

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Jul 25, 2024, 8:00 AM EDT - 8 months ago

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Jul 15, 2024, 9:02 AM EDT - 9 months ago

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Jul 10, 2024, 8:00 AM EDT - 9 months ago

Enveric Biosciences Announces Patent Granted for Drug Candidate

Jun 28, 2024, 8:00 AM EDT - 9 months ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

MBIO

Jun 25, 2024, 8:00 AM EDT - 10 months ago

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

May 30, 2024, 8:00 AM EDT - 10 months ago

Enveric Biosciences to Participate in BIO International Convention 2024

May 15, 2024, 6:00 AM EDT - 11 months ago

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 14, 2024, 10:35 AM EDT - 11 months ago

Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders

May 8, 2024, 7:00 AM EDT - 11 months ago

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Mar 12, 2024, 7:00 AM EDT - 1 year ago

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Feb 29, 2024, 7:00 AM EST - 1 year ago

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Feb 23, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Feb 21, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Jan 3, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Dec 29, 2023, 8:52 AM EST - 1 year ago

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

Dec 28, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Dec 27, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Dec 20, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”

Dec 5, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Nov 29, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

Nov 27, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Nov 24, 2023, 8:00 AM EST - 1 year ago

Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)

Nov 13, 2023, 4:01 PM EST - 1 year ago

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin

Oct 20, 2023, 8:00 AM EDT - 1 year ago

Enveric Biosciences to Present at the Centurion One 5th Global Summit

Oct 18, 2023, 8:00 AM EDT - 1 year ago

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit